Aclaris Therapeutics, Inc. Stock

Equities

ACRS

US00461U1051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
1.19 USD +0.85% Intraday chart for Aclaris Therapeutics, Inc. +1.71% +13.33%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 10.63M Sales 2025 * 10.68M Capitalization 84.81M
Net income 2024 * -53M Net income 2025 * -49M EV / Sales 2024 * -0.97 x
Net cash position 2024 * 95.15M Net cash position 2025 * 169M EV / Sales 2025 * -7.84 x
P/E ratio 2024 *
-1.59 x
P/E ratio 2025 *
-1.81 x
Employees 89
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.85%
1 week+1.71%
Current month-1.65%
1 month-3.25%
6 months+24.70%
Current year+13.33%
More quotes
1 week
1.14
Extreme 1.14
1.24
1 month
1.14
Extreme 1.14
1.40
Current year
0.86
Extreme 0.8555
1.51
1 year
0.59
Extreme 0.5902
11.12
3 years
0.59
Extreme 0.5902
24.00
5 years
0.59
Extreme 0.5902
30.38
10 years
0.59
Extreme 0.5902
33.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 12-06-30
Director of Finance/CFO 37 16-12-31
Chief Tech/Sci/R&D Officer - 21-09-30
Members of the board TitleAgeSince
Director/Board Member 58 17-08-08
Director/Board Member 66 19-07-01
Director/Board Member 66 17-01-24
More insiders
Date Price Change Volume
24-05-17 1.19 +0.85% 446,279
24-05-16 1.18 0.00% 406,521
24-05-15 1.18 0.00% 630,232
24-05-14 1.18 0.00% 631,183
24-05-13 1.18 +0.85% 683,674

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.19 USD
Average target price
1.84 USD
Spread / Average Target
+54.62%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW